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LETTER TO THE EDITOR
Reply to the letter from Janssen et al.
Sir - Numerous studies have revealed that the immunological
effects of treatment with recombinant interleukin 2 (rIL-2)
are dose and schedule dependent. Continuous and prolonged
treatment with rIL-2 leads to a sustained increase in the
number of natural killer (NK) cells and enhanced NK
activity (Caligiuri et al., 1993; Vlasveld et al., 1993). Janssen
et al. and others have shown that T-cell activation and
expansion also occur within the first weeks of treatment and
appear to be transient (Thompson et al., 1989; Yoshino et
al., 1991; Janssen et al., 1993). It is likely that we missed the
signs of T-cell activation because of the timing of the
immunological analysis in our study (Vlasveld et al., 1993).
In our recent study of continuous infusion of low-dose
rIL-2 and a monoclonal antibody directed against the B-cell-
specific antigen CD.19, we found signs of T-cell activation
(enhanced expression of CD25 and HLA-DR on CD3+ cells)
after 1 week of treatment and a transient increase in cir-
culating T cells during the first weeks of treatment in the
majority of patients (Vlasveld et al., unpublished data). The
proposed T-cell anergy occurring during prolonged rIL-2
treatment is in accord with experimental data that T cells
(especially CD4+) may become refractory to continued in
vitro exposure to IL-2 and revert to the resting stage (Can-
trell et al., 1983; Gulberg & Smith, 1986).
Although the role of cytotoxic T-cells in eradicating
tumours has been established in several animal models, in
man the anti-tumour effect of rIL-2-induced T-cell activation
has not been demonstrated. The limited anti-tumour effect
that we noted in our patients occurred during the first weeks
oftreatment, however it was not related to the observed signs
of activation ofcirculating T-cells (Vlasveld et al., 1992, 1993
and unpublished data).
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